Head and Neck Cancers An Overview of Treatment and Management
SELF STUDY / ENDURING - ESTIMATED TIME TO COMPLETE ACTIVITY: 60 Minutes
Primary treatment options for head and neck cancers (surgery, radiation, and chemotherapy) and immunotherapy for metastatic disease all require different management and adverse event consideration. In this webcast, expert faculty will review the primary types of head and neck cancers, the roles of various treatments recommendations, and considerations for managing treatment-related complications and adverse events. Advanced practice providers participating in this program will be equipped with the knowledge and strategies needed to improve the treatment and management of patients with head and neck cancers.
This CME initiative was designed for oncologists, surgeons, radiation oncologists, NPs, PAs, pharmacists, nurses, and other healthcare professionals involved in the treatment of patients with cancer.
1. Identify the 5 main types of head and neck cancers and their etiologies
2. Compare and contrast the roles of surgery, radiation, chemotherapy and immunotherapy in the management of patients with head and neck cancer
3. Identify the acute and delayed post-treatment complications that are common in patients with head and neck cancer
4. Review strategies that APPs can employ to manage post-treatment complications
Kedar Kirtane MD
Dr. Kirtane is an Assistant Member at Moffitt Cancer Center in the Department of Head and Neck-Endocrine Oncology. Dr. Kirtane received his MD degree from the University of Florida College of Medicine. He completed an Internal Medicine Residency at Duke University Medical Center. Dr. Kirtane completed a Hematology/Oncology Fellowship at the University of Washington and a Post-Doctoral Fellowship in Oncology at the Fred Hutchinson Cancer Research Center in Seattle, Washington. His clinical focus is patients with head and neck endocrine cancers. He is interested in working with the Department of Health Outcomes and Behavior and the Department of Cancer Epidemiology to help increase access to cancer care for racial/ethnic minorities with cancer. Dr. Kirtane's research interests include the development of innovative cellular therapies for HPV-related malignancies. patients with head and neck endocrine cancers. He is interested in working with the Department of Health Outcomes and Behavior and the Department of Cancer Epidemiology to help increase access to cancer care for racial/ethnic minorities with cancer. Dr. Kirtane's research interests include the development of innovative cellular therapies for HPV-related malignancies.
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Horizon CME (HCME) ensures that continuing education activities are balanced, independent, objective, and scientifically rigorous.
All persons in a position to influence the content of an accredited continuing education activity provided by Horizon CME are required to disclose to HCME any relevant financial relationships with ineligible companies within the past 24 months. All reported relevant financial relationships have been mitigated by Horizon CME.
Kedar Kirtane discloses no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients during the past 24 months.
- 1.00 AMA PRA Category 1 Credit™Horizon CME designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 ANCCThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. This course is approved by the Nurse Practitioner Healthcare Foundation, California Board of Registered Nursing, CEP# 16441. Upon completion, NPs and RNs will be awarded up to 1.00 credit.
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Complete the post-test and score a minimum of 70%
- Submit the evaluation form.
Access to the internet is required.
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
DISCLOSURE OF UNLABELED USE:
Horizon CME requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.